RedHill Biopharma Ltd.
RDHL · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $2 | $2 | $3 | $3 |
| % Growth | 0% | -25.4% | 0% | – |
| Cost of Goods Sold | $1 | $1 | $1 | $1 |
| Gross Profit | $1 | $1 | $2 | $2 |
| % Margin | 60.6% | 60.6% | 67.3% | 67.3% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $2 | $2 | $2 | $2 |
| SG&A Expenses | $3 | $3 | $3 | $3 |
| Sales & Mktg Exp. | $1 | $1 | $1 | $1 |
| Other Operating Expenses | $0 | $0 | $1 | $1 |
| Operating Expenses | $3 | $3 | $5 | $5 |
| Operating Income | -$2 | -$2 | -$3 | -$3 |
| % Margin | -107.3% | -107.3% | -112.7% | -112.7% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$2 | -$2 | -$3 | -$3 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | -$2 | -$3 | -$3 |
| % Margin | -101.3% | -101.3% | -94.7% | -94.7% |
| EPS | -1 | -1 | -1 | -1 |
| % Growth | 0% | 0% | 0% | – |
| EPS Diluted | -1 | -1 | -1 | -1 |
| Weighted Avg Shares Out | 2 | 2 | 3 | 3 |
| Weighted Avg Shares Out Dil | 2 | 2 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1 | $1 |
| Interest Expense | $1 | $1 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$2 | -$2 | -$2 | -$2 |
| % Margin | -103.2% | -103.2% | -68.7% | -66.4% |